Trump administration authorises 172 million barrel SPR drawdown as 32 IEA nations coordinate record emergency oil release
Read More 4 minute read Pharma Industry News Nutshell Therapeutics secures FDA IND clearance for NTS071, targeting p53 Y220C mutation in cancer treatment Find out how Nutshell Therapeutics’ NTS071 is redefining precision oncology by targeting the p53 Y220C mutation with a novel allosteric small molecule. byPallavi MadhirajuMay 4, 2025